OFIX
Orthofix Medical Inc. (NASDAQ)
Healthcare — Medical Devices
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Price History
Fundamentals
| Market Cap | $377.94M |
| P/E Ratio (TTM) | - |
| Forward P/E | 13.17 |
| EPS (TTM) | $-1.50 |
| Dividend Yield | - |
| Profit Margin | -7.27% |
| Revenue Growth | 1.60% |
| ROE | -13.43% |
| Debt/Equity | 60.26 |
| Recommendation | Buy 2.0 |
| Analyst Target | $15.00 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 44.7 |
| Beta | 0.72 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.99 |
| 52-Week Low | $8.85 |
| 50-Day Avg | $10.67 |
| 200-Day Avg | $13.26 |
| Avg Volume | 391.5K |
| Volume | 422.0K |
Performance Analysis
NEUTRALOFIX presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:24 UTC
Back to Screener Export Report